SOPH — SOPHiA GENETICS Reports Third‑Quarter 2026 Results; Announces ARC Regulatory Collaboration on EU Clinical‑trial Assay Support
Confirmed — SOPHiA GENETICS (SOPH) published third‑quarter 2026 financial results and separately released a collaboration with ARC Regulatory to support EU clinical‑trial assay development. No line‑item financial metrics are present in the supplied market data; open the company IR links to confirm reported revenue, EPS or guidance.